Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

We evaluated the efficacy of metronomic etoposide or temozolomide administered with bevacizumab among recurrent glioblastoma (GBM) patients who progressed on prior bevacizumab therapy in a phase 2, open-label, two-arm trial. Twenty-three patients received bevacizumab (10 mg/kg) every 2 weeks with ei...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Reardon, David A., Desjardins, Annick, Peters, Katherine, Gururangan, Sridharan, Sampson, John, Rich, Jeremy N., McLendon, Roger, Herndon, James E., Marcello, Jennifer, Threatt, Stevie, Friedman, Allan H., Vredenburgh, James J., Friedman, Henry S.
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3102515/
https://ncbi.nlm.nih.gov/pubmed/20853132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-010-0403-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires